Migenix enrolls in phase 2b celgosivir, pegetron Hepatitis C study

By Jennifer Chiou

New York, Nov. 22 - Migenix Inc. said it initiated enrollment in a phase 2b combination therapy clinical trial of celgosivir, supported in part through an agreement with Schering-Plough for pegetron.

Celgosivir is an orally administered alpha glucosidase 1 inhibitor in development for the treatment of chronic hepatitis C virus infections.

The study is randomized, multi-center and active controlled.

"With the large market potential and unmet need in current hepatitis C treatment, celgosivir is an important component of our value proposition in the short term," Migenix president and chief executive officer Jim DeMesa said in a news release.

"Based on its strong demonstration of synergy in non-clinical studies to date, celgosivir shows great promise as part of a combination therapy approach to improving the success of treatment for patients suffering from chronic hepatitis C infections."

Vancouver, B.C.-based Migenix is focused on drug development for infectious and degenerative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.